Renovia Inc. (“Renovia”) is a startup firm focused on new innovations regarding women’s health. Renovia was co-founded by Marc Beer. Through his leadership as Chief Executive Officer (CEO) of the firm, they have secured a Series B round of funding to the tune of $32 million together with $10 million in venture debt. The funding will be used to expand the efforts of Renovia to develop products to treat and improve the health of millions of women affected by pelvic floor disorders such as urinary incontinence. The first such product developed by Renovia, Leva, was approved by the Food and Drug Administration (FDA) in April of 2018.
This round of funding was backed by three leading investors in the healthcare sector: Perceptive Advisors, Ascension Ventures and the Longwood Fund. Doubtless, the confidence in Renovia’s research and development efforts expressed by these investors is due to the stellar reputation of Renovia’s co-founder and CEO, Marc Beer. Mr. Beer previously worked as a strategic consultant at the publically traded biotechnology firm OvaScience (Nasdaq: OVAS). In August 2018, OvaScience indicated that they would be merging with Millendo Therapeutics.
Marc Beer boasts an executive career that has spanned over 25 years. This includes development and market launch expertise in diagnostic, device, biotech and pharmaceutical enterprises. Mr. Beer was the founding CEO of ViaCell back in April of 2000. This biotech firm developed unique products focused on umbilical cord blood stem cells. Under Beer’s leadership, ViaCell grew into a company of over 300 employees. They went public in 2005 and were subsequently acquired by PerkinElmer (NYSE: PKI) in 2007. During his tenure at ViaCell, Mr. Beer was also a member of the Board of Directors at Erytech Pharma (Nasdaq: EPYP). Learn more: https://www.crunchbase.com/person/marc-beer
Before taking on his role as CEO of ViaCell, Bell held a number of executive positions at Genzyme. As Vice President of Global Marketing, he oversaw the global launch of a number of products that targeted rare disease populations worldwide. Preceding his role at Genzyme, Marc served in a number of marketing and sales positions in the diagnostic and pharmaceutical divisions of Abbott Laboratories. Furthermore, Marc previously served on the Biotechnology Industry Organization Emerging Companies Section Governing Board